The American Society of Clinical Oncology (ASCO) is governed by a volunteer Board of Directors (including four Board officers) elected by ASCO’s member oncologists. The Chief Executive Officer serves on the Board as well. Elected Board members are cancer physicians and clinical researchers who volunteer their time to ASCO. Board members are not paid for their service, although their institutions receive stipends to partially cover the time and administrative resources dedicated to ASCO.
ASCO’s financial and other disclosures are governed by its own Policy for Relationships With Companies, the Council of Medical Specialty Societies’ CMSS Code for Interactions with Companies, and the Accreditation Council for Continuing Medical Education Standards. Consistent with the CMSS Code (Article IV, Section 2.4), ASCO here discloses the financial and uncompensated relationships between the Board of Directors and companies with a commercial interest in the science or practice of oncology.
Please direct any questions to COI@asco.org.
View the disclosures for the ASCO Board of Directors as of September 2017.
Dr. Hudis is the Chief Executive Officer of the American Society of Clinical Oncology (ASCO). He also serves as the CEO of its Conquer Cancer Foundation and the Chairman of the Board of Governors of ASCO’s CancerLinQ. Dr. Hudis previously served in a variety of roles at ASCO, including as President during the Society’s 50th anniversary year (2013-14). Before transitioning full-time to ASCO, he was the Chief of the Breast Medicine Service at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City, where he was also Professor of Medicine at the Weill Medical College of Cornell University. In this role, he developed more effective treatments for all stages of breast cancer, while also exploring novel prevention opportunities. As CEO of ASCO, Dr. Hudis’ focus is on education, research and promotion of the highest quality of care by the Society’s nearly 45,000 members. Key initiatives include the acceleration of CancerLinQ, ASCO’s focused effort to increase insights and learning from the rapidly accumulating electronic records of routine care provided by clinicians.
Monica M. Bertagnolli, MD, FACS, FASCO, is chief of the division of Surgical Oncology at Dana-Farber/Brigham and Women’s Cancer Center, a professor of surgery at Harvard Medical School, and an associate surgeon at Brigham and Women’s Hospital and Dana-Farber Cancer Institute. She has worked at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital since 2000. She previously served as an associate surgeon at the Strang Cancer Prevention Center in New York from 1994-2007 and as an attending surgeon at New York Presbyterian Hospital–Cornell from 1994-1999.
Since joining ASCO in 1995, Dr. Bertagnolli has served on the Board of Directors (2007-2011), as well as on numerous committees, including the ASCP/CAP/AMP/ASCO Colorectal Cancer Guidelines Committee (co-chair 2011-present), the Cancer Prevention Committee (2001-2004 and 2007-2010), and the Planning Committee (2008-2011), among others.
In addition to her ASCO involvement, Dr. Bertagnolli currently serves as vice president of Coalition of Cancer Cooperative Groups, group chair of Alliance for Clinical Trials in Oncology, president of the Alliance for Clinical Trials in Oncology Foundation, and CEO of Alliance Foundation Trials, LLC. Since 2012 she has served on the on the National Academy of Medicine’s National Cancer Policy Forum. In 2011, she received the Partners Healthcare Partners in Excellence Award: Personalized Cancer Medicine Partnership Team, and in 2015, she received the CEO Roundtable on Cancer Charles H. Sanders Life Sciences Award.
Dr. Bertagnolli received her undergraduate degree from Princeton University and her medical degree from the University of Utah College of Medicine; she performed her residency at Brigham and Women’s Hospital.
Howard "Skip" Burris III, MD, FACP, FASCO serves as president and chief medical officer of Sarah Cannon, as well as the executive director, drug development for the research institute. He is an associate of Tennessee Oncology, PLLC, where he practices medical oncology.
Dr. Burris' clinical research career has focused on the development of new cancer agents with an emphasis on first in human therapies, having led the trials of many novel antibodies, small molecules, and chemotherapies now approved, including ado-trastuzumab emtansine, everolimus, and gemcitabine. In 1997, he established in Nashville the first community based early phase drug development program, which grew into the Sarah Cannon Research Institute. He has authored over 400 publications and 700 abstracts.
Since joining ASCO in 1991, Dr. Burris has been elected and served as a member of the ASCO Board of Directors (2006-2009) as well as Chair of the Nominating Committee (2012-2013), and he currently serves on the Board of ASCO’s Conquer Cancer Foundation. His committee memberships have included service on Cancer Research, Education, Scientific Program, Research Community Forum, Ethics, Audit, and Sponsorship Committees. Additionally in 2014, Dr. Burris was selected by his peers as a Giant of Cancer Care for his achievements in drug development.
Dr. Burris completed his undergraduate education at the United States Military Academy at West Point, his medical degree at the University of South Alabama, and his internal medicine residency and oncology fellowship at Brooke Army Medical Center in San Antonio. While in Texas, he also served as the Director of Clinical Research at The Institute for Drug Development of the Cancer Therapy and Research Center and The University of Texas Health Science Center. He attained the rank of lieutenant colonel in the US Army, and among his decorations, he was awarded a Meritorious Service Medal with oak leaf cluster for his service in Operation Joint Endeavor.
Bruce E. Johnson, MD, FASCO, is Chief Clinical Research Officer and Institute Physician at the Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School. He is the Director of the Dana-Farber/Harvard Cancer Center (DF/HCC) Lung Cancer Program. He stepped down as the Director of the Lowe Center for Thoracic Oncology, a position he held beginning in 1998 through 2013.
An ASCO member since 1985, Dr. Johnson has served in numerous volunteer and leadership roles, including the Board of Directors (2008-2011), Chair of the Audit, Cancer Education, and Cancer Communications Committees, and on the Journal of Clinical Oncology Editorial Board, among other positions. In 2008, he was award the Translational Research Professorship from the Conquer Cancer Foundation of ASCO.
Dr. Johnson has been active on committees and study sections within the National Cancer Institute, including recent service on the Special Emphasis Panel to review SPOREs, the Clinical Oncology Study Section, and on the Thoracic Malignancy Steering Committee, among others. He has served on a number of external advisory boards, including the External Advisory Committee for The Cancer Genome Atlas. He is a member of the Scientific Advisory Board for The University of Texas MD Anderson Moon Shots Program, and is active in the American Association for Cancer Research (AACR) and the International Association for the Study of Lung Cancer (IASLC), as well as other professional organizations. He was awarded the IASLC Scientific Award in 2009. In 2010, he was one of the leaders of the team honored with the AACR Team Science Award. He was elected to the Association of American Physicians in 2015.
Dr. Johnson earned his undergraduate degree from Harvard University and his medical degree from the University of Minnesota. He completed his internship and residency in internal medicine at the University of Chicago Hospitals and Clinics. He concluded his training as a Clinical Associate at the National Cancer Institute.
Laurie E. Gaspar, MD, MBA, FACR, FASTRO, grew up in Toronto, Ontario and completed medical school and a residency in radiation oncology at the University of Western Ontario. Later, after moving to the United States she completed her Masters of Business Administration (MBA) at the University of Michigan.
Dr. Gaspar has been active in many national and international committees, including the ASCO Publications Committee and ASCO’s Annual Program Committees. She is also involved with the American College of Radiology (ACR), the American Board of Radiology (ABR), the American Society for Radiation Oncology (ASTRO), NRG (formally RTOG), the International Society for the Study of Lung Cancer (IASLC), and SWOG. She is a Co-Chair of the NCI Thoracic Malignancy Steering Committee. Dr. Gaspar is on the editorial board of Clinical Lung Cancer and Advances in Radiation Oncology. She is the author of more than 200 academic articles.
Dr. Gaspar was Professor and Chair of the Department of Radiation Oncology at the University of Colorado for more than 15 years. She is currently Professor Emeritus in the Department of Radiation Oncology at the University of Colorado with continued interest in the management of brain tumors and lung cancer. Dr. Gaspar also has ongoing research in patient communication and advocacy, and shared decision making.
Peter C. Adamson, MD, is Chair of the Children’s Oncology Group, President of the Children’s Oncology Group Foundation, and a Professor of Pediatrics and Pharmacology at The Children’s Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania. He has been a faculty member at the University of Pennsylvania since 1999.
Since joining ASCO in 1992, Dr. Adamson has served on the Cancer Research Committee (2011-2014) and the Scientific Program Committee (2007-2010), and on the Editorial Board of the Journal of Clinical Oncology (2007-2010).
In 2015 President Barack Obama appointed Dr. Adamson to the National Cancer Advisory Board. Dr. Adamson has previously served on the American Association of Cancer Research Pediatric Steering Committee (2011-2015), the National Cancer Institute’s Experimental Therapeutics Program (NExT) Special Emphasis Panel (2012-2015), as the Chair of Children’s Oncology Group Developmental Therapeutics Program (2000-2008), on the National Cancer Institute’s Investigational Drug Steering Committee (2005-2012), and on the Department of Defense Neurofibromatosis Research Programmatic Review Committee (1999-2004).
Dr. Adamson received his undergraduate degree from Wesleyan University and his medical degree from Cornell University Medical College. He performed his residency at The Children’s Hospital of Philadelphia and his fellowship in the Pediatric Oncology Branch of the National Cancer Institute.
A. William Blackstock, MD, FASCO is Professor and Chair of the Department of Radiation Oncology at the Wake Forest University (WFU) School of Medicine and Director of the Clinical Research Program at the Comprehensive Cancer Center at Wake Forest Baptist Medical Center. He received his undergraduate degree from WFU and his medical degree from the East Caroline University Brody School of Medicine. He completed a residency in radiation oncology at the University of North Carolina at Chapel Hill and a three-year NCI-funded fellowship in translational Radiation Oncology. He has been Chair at WFU for the past 8 years.
Dr. Blackstock remains active in translational clinical research, having served as vice-chair of the GI Committee in the Alliance/CALGB cooperative group and co-vice chair of the Radiation Oncology committee. In addition to serving on the NCI Clinical Oncology study section (2003-2006), he served on the NCI Pancreatic Task Force, Gastrointestinal Steering committee and co-chair of the Thoracic Malignancy Steering Committee (2013-2016). He recently completed service on the NCI Board of Scientific Counsel Intramural Program.
Dr. Blackstock has been an active ASCO member for almost 20 years, serving on the grants selection and communications committees. He has chaired the Gastrointestinal Cancer Program subcommittee and the ASCO membership committee (2008-2009). Other activities include participating in the ASCO Leadership Development Working Group and Health Disparities Advisory Group.
Dr. Blackstock has been the lead investigator of several NCI-funded grants including principal investigator of an NCI-funded T32 fellowship focused on Translational Radiation Oncology. He currently serves on the external advisory board for several NCI/NIH funded training programs. He has published over 100 peer-reviewed manuscripts and book chapters and has/is currently serving on the editorial board for several journals including the Journal of Clinical Oncology (2007-2009).
Stephen B. Edge, MD, FACS, FASCO, is the Vice President for Healthcare Outcomes Policy and Professor of Oncology at the Roswell Park Cancer Institute.
Since joining ASCO in 1988, Dr. Edge has co-chaired the 2010 Breast Cancer Symposium and Guideline Panel for Postmastectomy Radiation. He is currently serving on the Cancer Prevention and Audit Committees, as well as the Editorial Boards of the Journal of Oncology Practice, the Journal of Clinical Oncology, and Cancer.Net. He has also served on the Health Services Research Committee, the inaugural Quality Care Symposium Planning Committee, and as the Health Services Research Track Leader for the ASCO Annual Meeting.
Dr. Edge serves as Immediate Past Chair of the Commission on Cancer, on the Cancer Support Community Policy Institute of the National Advisory Board. He was the Co-Chair of the Technical Advisory Panel for Quality Measure Development in Oncology for the National Committee on Quality Assurance, and is now on the Centers for Medicare & Medicaid Services’ Hospital Inpatient and Outpatient Process and Structural Measure Development and Maintenance Panel.
He received his undergraduate degree from Tufts University and his medical degree from Case Western Reserve University; he performed his internship and residency at University Hospitals of Cleveland. His fellowship was completed at the Surgery Branch of the National Cancer Institute.
Lee M. Ellis, MD, FACS, FASCO, is the William C. Liedtke Jr. Chair in Cancer Research and a professor in the Departments of Surgical Oncology and Molecular & Cellular Oncology at The University of Texas MD Anderson Cancer Center (MDACC), as well as the vice chair of Translational Medicine at SWOG. Previously, he served as interim chair, Department of Cancer Biology from 2008 to 2012, director of the Metastasis Research Center from 2010 to 2012, and director of the Colorectal Cancer Translational Research Program from 2007 to 2013, all at MDACC.
Since joining ASCO in 1994, Dr. Ellis has served on numerous committees with recent committee service on the Nominating Committee (2013-2016; chair, 2015-2016), the Best Practices in Clinical Cancer Trials Workshop (2015-2016), the Cancer Research Committee (2011-2014; chair 2012-3013), and the Cancer Education Committee (2011-2013; Tumor Biology track leader, 2012-2013). He served as a faculty member of the ASCO/AACR Methods in Clinical Cancer Research Workshop in 2007-2013 and was co-director in 2010-2013. He was named a Fellow of ASCO (FASCO) in 2014, and he currently serves on the ASCO Special Awards Selection Committee and the Leadership Development Working Group.
In addition to his ASCO involvement, Dr. Ellis serves as the co-chair of the National Cancer Institute's (NCI) National Clinical Trials Network Core Correlative Sciences Committee, vice chair of the NCI Colon Cancer Task Force (2011-2018), and Vice Chair of the Hope Foundation, SWOG’s philanthropic arm. Dr. Ellis has a special interest in preclinical data reproducibility, and has published several important manuscripts in this area. He has also met with NCI, NIH, and National Academies of Science (NAS) leaders regarding the importance of this issue and how to address this problem. Dr. Ellis has also served on a NAS committee that focused on issuing recommendations to decrease the regulatory burden of research (2014-2016), and as faculty and then co-director (2015-present) of the ECCO-AACR-EORTC-ESMO workshop on Methods in Clinical Cancer Research in Europe. In 2017, Dr. Ellis received the Flance-Karl Award from the American Surgical Association for his “seminal contributions in understanding colorectal cancer biology.” He currently serves on several data safety monitoring committees and the Scientific Audit Committee of the EORTC (Brussels, Belgium).
Dr. Ellis received his medical degree from the University of Virginia; he performed his residency at the University of Florida, and his fellowship at MDACC.
Arti Hurria, MD, FASCO, is vice provost of clinical faculty, professor and director of the Center on Cancer and Aging, and co-lead of the Cancer Control and Population Sciences Program at City of Hope. Dr. Hurria has been a faculty member at City of Hope since 2006.
Since joining ASCO in 2001, Dr. Hurria has served on several ASCO committees. She is Leader of the ASCO Geriatric Oncology Special Interest Group, Chair of the Professional Development Committee, Chair-Elect of the Cancer Research Committee, Associate Editor of the Cancer.Net Editorial Board, and a member of the Journal of Clinical Oncology Editorial Board. She has served on the Special Awards Selection Committee, as a Track Leader of the Cancer Education Committee, Chair of the Lifelong Learning Subcommittee, and on the Task Force on ASCO Volunteer Groups. Dr. Hurria is also a previous participant in the Leadership Development Program and recipient of the Conquer Cancer Foundation of ASCO’s Young Investigator Award and Career Development Award.
In addition to her ASCO involvement, Dr. Hurria is Chair and Founder of the Cancer and Aging Research Group, Co-Chair for the Alliance Cancer in the Elderly Committee, Past President of the International Society of Geriatric Oncology, and Past Chair of the National Comprehensive Cancer Network Older Adult Oncology Committee (2010-2016). She has received many awards and honors, including ASCO’s B. J. Kennedy Award for Scientific Excellence in Geriatric Oncology, the International Society of Geriatric Oncology’s Paul Calabresi award. the Paul B. Beeson Career Development Award in Aging (K23), and the Frederick Stenn Memorial Award for Humanism in Medicine.
She received her medical degree from Northwestern Medical School; she completed her internship at Beth Israel Medical Center, her residency at Beth Israel Deaconess Medical Center, and her fellowships in Geriatrics and Oncology at the Harvard Geriatrics Fellowship Program and Memorial Sloan Kettering Cancer Center, respectively.
Maha Hussain, MD, FACP, FASCO, is the Genevieve Teuton Professor of Medicine in the Division of Hematology Oncology, Department of Medicine, and the Deputy Director, and leader of the GU Oncology Program at the Robert H. Lurie Comprehensive Cancer Center of the Northwestern University Feinberg School of Medicine.
Dr. Hussain received her medical degree from Baghdad University College of Medicine and performed her residency and fellowship at Wayne State University.
Dr. Hussain is a practicing oncologist, internationally renowned expert and clinical researcher in genitourinary oncology particularly prostate and bladder cancer. Her research is focused on the development of novel therapeutics integrating scientific advances into clinical trials. Her clinical research has contributed to impacting the standards of care for patients with metastatic hormone sensitive and castration resistant prostate cancer. She is also an educator and mentor and have guided the career development of many fellows and young faculty at Wayne State University and the University of Michigan several of whom have chosen an academic career in GU Oncology.
At the national level Dr. Hussain has served in a variety of scientific leadership roles, including the Co-Chair of the SWOG Prostate Cancer Subcommittee (1994-2012), member (2009-2014) and Chair (2013-2014) of the Integration Panel of the U.S. Army Medical Research and Materiel Command Prostate Cancer Research Program, and was a member (2004-2008) and Chair (2007-2008) of the U.S. Food and Drug Administration Oncology Drug Advisory Committee. Dr. Hussain was a member of the NCI Cancer Biomarker Study Section and the NCI’s Prostate cancer task force. She currently serves as an EAB member for several NCI-designated cancer centers and the UCLA Prostate Cancer SPORE.
Since joining the American Society of Clinical Oncology in 1990, Dr. Hussain has served on numerous committees and boards, including the Scientific Program, Cancer Education, International Affairs, and Cancer Communications committees. In addition, she chaired the Cancer Education Committee (2008-2009), the Genitourinary Cancers Symposium Program Committee (2010-2011) and the Genitourinary Cancers Symposium Steering Committee (2013-2014) and was Associate Editor for Cancer.Net. She currently serves on the Clinical Practice Guidelines Committee and is an elected member of the ASCO Board of Directors.
Dr. Hussain is the author of more than 250 scholarly articles and book chapters. She serves/has served on the editorial boards for several national and international specialty publications. She has been invited to give hundreds of lectures on her work in the United States and many countries around the world.
Dr. Hussain has received many honors, including the University of Michigan Comprehensive Cancer Center Leadership Award (2007), the University of Michigan Medical School League Of Research Excellence (2011), and the 2012 Clinical & Health Services Research Award. She was elected as a Fellow of ASCO (2010). She has been named for many years in America’s Top Doctors” and “America´s Top Doctors for Cancer. In 2015 she was named one of OncLive’s Giants of Cancer Care and in 2017 she was named Castle Connolly Exceptional Women in Medicine.
Reshma Jagsi, MD, DPhil, is professor and deputy chair of the Department of Radiation Oncology at the University of Michigan, where she is residency program director, treats breast cancer, and conducts health services research.
An ASCO member since 2004, Dr. Jagsi currently serves on the CancerLinQ® Data Governance Oversight Committee and the Bisphosphonates in Breast Cancer and Breast Cancer Consensus Expert Panels. She is a past chair of the Ethics Committee (member 2014-2016; chair 2014-2015). She has served on the Scientific Program Committee (2010-2012), and the Journal of Clinical Oncology (JCO) Editorial Board (2013-2015). Dr. Jagsi participated in ASCO’s Leadership Development Program in 2011-2012 and served as an ASCO representative to the American Medical Association.
Dr. Jagsi leverages her research expertise to extend her ASCO service, having published in The New England Journal of Medicine, JAMA, and JCO on issues directly related to her ASCO committee and advocacy experiences. She has an active R01 grant from the National Cancer Institute to study the ethical implementation of CancerLinQ. She has also been active in ASCO’s efforts to promote gender equity (the subject of another R01-funded research program she leads), through its Women’s Networking Center.
Dr. Jagsi received her undergraduate and medical degrees from Harvard, and her doctorate in Social Policy from Oxford as a Marshall Scholar. She completed her residency at the Massachusetts General Hospital/Harvard Radiation Oncology Program (where she was chief resident), as well as a fellowship at the Harvard Center for Ethics.
Michael P. Kosty, MD, FACP, FASCO, is a member of the Scripps Green Cancer Center where he has practiced hematology and medical oncology since 1989. He has served as the director of Scripps Green Cancer Center in La Jolla, California, since 2008, director of Graduate Medical Education at Scripps Clinic/Scripps Green Hospital since 2002, and as director of the Hematology/Oncology Fellow Training Program at Scripps Clinic/Scripps Green Hospital since 1997. Since 1990, he has served at Scripps Green Cancer Center as head of the Thoracic Oncology Service, and as a member of the Genitourinary Oncology Service, Dermatologic Oncology Service, and the Clinical Research Advisory Committee.
Since joining ASCO in 1986, Dr. Kosty has served as the chair of the Continuing Medical Education Subcommittee (2013-2014), chair of the Oncology Training Program Subcommittee (2009-2010), chair of the Workforce Advisory Group (2015-2016), and is currently the chair-elect of the Professional Development Committee. In addition, he also served as a member of the Test Materials Development Committee and is ASCO co-chair of the European Society of Medical Oncology–ASCO Global Curriculum Workgroup. In recognition of his years of service to ASCO, Dr. Kosty received the distinction of Fellow of ASCO (FASCO) in 2014.
Dr. Kosty served as an investigator for the Southwest Oncology Group from 1999 to 2007 and as an investigator for the Cancer and Leukemia Group B from 1986 to 1999. Dr. Kosty dedicated many years to service in the military, as a general medical officer on the USS Belleau Wood (LHA-3; 1980-1981), as an attending physician and assistant head in the Division of Hematology/Oncology at the Naval Hospital (1986-1989), and as a member of the U.S. Naval Reserve (1989-1999).
Dr. Kosty received his undergraduate and master’s degrees from the University of California, Berkeley. He received his medical degree from George Washington University; he performed his internship, residency, and fellowship at Naval Hospital, San Diego. He was a visiting fellow at the Dana-Farber Cancer Institute at Harvard Medical School and a research fellow at the Scripps Clinic and Research Foundation.
Tony S. K. Mok, BMSc, MD, FRCP(C), FRCP(Edin), FHKCP, FHKAM(Medicine), FASCO, was trained at the University of Alberta, Canada and he subsequently completed a fellowship in medical oncology at the Princess Margaret Hospital in Canada. After working as a community oncologist in Toronto, Canada for seven years, he returned to Hong Kong in 1996 to pursue an academic career.
He is Li Shu Fan Medical Foundation Named Professor of Clinical Oncology and Chairman of Clinical Oncology at The Chinese University of Hong Kong (Hong Kong). His main research interest focuses on biomarker and molecular targeted therapy in lung cancer. He co-founded the Lung Cancer Research Group, and has led a number of important multinational clinical trials, which include the IPASS (IRESSA Pan-Asia Study), a landmark study that established the role of first-line gefitinib in patients with EGFR mutation.
Prof. Mok has contributed to over 220 articles in international peer-reviewed journals, including the New England Journal of Medicine, Science, Lancet and Journal of Clinical Oncology, and contributed to multiple editorials and textbooks. He is active and experienced in serving the academic societies. He is now Fellow of American Society of Clinical Oncology (FASCO), Past Chair of the ASCO International Affairs Committee, Treasurer and Past President of the International Association for the Study of Lung Cancer (IASLC), a member of the ASCO Publications Committee and Vice Secretary of the Chinese Society of Clinical Oncology (CSCO).
He is closely affiliated with the oncology community in China, and has received an Honorary Professorship at Guang Dong Province People’s Hospital, Guest Professorship at Peking University School of Oncology, Visiting Professorship at Shanghai Jiao Tong University and West China School of Medicine/West China Hospital, Sichuan University. He is an Associate Editor on Thoracic Oncology for Journal of Clinical Oncology. He has also authored eight books in Chinese and hosted three television series in Hong Kong.
J. Chris Nunnink, MD, FASCO, is an Attending Physician in Medical Oncology at the University of Vermont Medical Center (UVMMC ) and an Associate Professor at the Vermont Cancer Center and the College of Medicine at the University of Vermont, where he is developing a network for oncology care in rural upstate New York and Vermont. Before transitioning to UVMMC, he started a large private practice, the Vermont Center for Cancer Medicine, and ran this successful practice for 27 years.
Since joining ASCO in 1986, Dr. Nunnink currently serves on the Clinical Practice Committee. He has served on the State Affiliate Council and was the ASCO advisor to the Relative Value Scale Update Committee of the American Medical Association (AMA). Dr. Nunnink was elected as a Fellow of ASCO (FASCO) in 2011. He has served as an ASCO delegate to the AMA since 2010.
Dr. Nunnink is a member of the National Surgical Adjuvant Breast and Bowel Project, Cancer and Leukemia Group B/Alliance, and Cancer Committee at FAHC. He served as a Trustee for the Fanny Allen Hospital from 1994 to 1996 (when it merged with the Medical Center Hospital of Vermont to form UVMMC), President of the Northern New England Clinical Oncology Society in 2001 and 2007, and Vermont delegate to the AMA from 2007-2010.
Dr. Nunnink received his undergraduate degree from Indiana University and his medical degree from the College of Medicine at the University of Vermont; he performed his internship and residency at the Medical Center Hospital of Vermont and his fellowship at the Wisconsin Clinical Cancer Center.
Dr. Roberts is a Managing Member and portfolio manager at Farallon Capital Management, LLC. Prior to joining Farallon, Dr. Roberts was an attending oncologist at Massachusetts General Hospital, an Instructor of Medicine at the Harvard Medical School, and a Visiting Scientist at Massachusetts Institute of Technology. Dr. Roberts obtained two baccalaureate degrees (Summa Cum Laude) from the University of Pennsylvania, including a Bachelors of Science from the Wharton School of Business (Phi Beta Kappa junior year). He obtained his medical degree from Harvard Medical School. Dr. Roberts performed his internal medicine training at the Massachusetts General Hospital and his medical oncology training through the Dana-Farber/Partners Cancer Care Oncology Fellowship Program. Dr. Roberts has been an ASCO member since 2003.
Eric J. Small, MD, FASCO, is the deputy director of the UCSF Helen Diller Family Comprehensive Cancer Center, chief of the Division of Hematology and Oncology in the Department of Medicine at the University of California, San Francisco, and professor in residence in the Department of Medicine and Department of Urology. Dr. Small has worked at the University of California, San Francisco since 1988.
Since joining ASCO in 1992, Dr. Small has served as an associate editor for the Journal of Clinical Oncology (2008-2013), chaired the Molecular Markers Scientific Committee (2008-2009), chaired the Scientific Program Committee (2003-2004), served as the inaugural chair of the Prostate Cancer Symposium Steering Committee, and served as chair of the Prostate Cancer Symposium Program Committee (2004-2005). Dr. Small has chaired the grant writing workshop at the ASCO Annual Meeting. Dr. Small also served on the Nominating Committee (2007-2010) and the Conquer Cancer Foundation Grands Selection Committee (2009-2012), among other commitments. Dr. Small was named a Fellow of ASCO (FASCO) in 2015.
In addition to his ASCO involvement, Dr. Small is a member of the National Cancer Institute Initial Review Group Subcommittee A (Parent Committee for Cancer Centers, 2010-present), a member of the National Cancer Center Network Treatment Guidelines Panel (1999-present), and leads a 40-member Stand Up to Cancer Dream Team. Dr. Small served as chair of the CALGB (Alliance) Genitourinary Committee for 14 years, and in 2011, was awarded the Richard L. Schilsky CALGB Award.
Dr. Small received his undergraduate degree from Stanford University and his medical degree from Case Western Reserve University School of Medicine. He performed his internship and residency at Beth Israel Hospital (Boston), and completed his fellowship at the University of California, San Francisco.
Jaap Verweij, MD, PhD, FASCO, is a medical oncologist and currently vice-Dean of the Faculty of Medicine at Erasmus University, Rotterdam, the Netherlands, as well as the Founding Dean of the Faculty of Life Sciences at the University of Siegen, Germany. Dr. Verweij has been a faculty member of Erasmus University Medical Center since 1984.
Since joining ASCO in 1986, Dr. Verweij has served as Associate Editor of the Journal of Clinical Oncology and a member of the Scientific Program Committee, Conquer Cancer Foundation Grants Selection Committee, Multidisciplinary Cancer Management Committee, and Cancer Education Committee.
In addition to his ASCO involvement, Dr. Verweij currently serves as Vice-Chair of the Supervisory Board of the Dutch Cancer Foundation, a member of the Scientific Advisory Board for Aarhus University, a Fellow of The Royal Netherlands Academy of Arts and Sciences, and a member of the Supervisory Board of the Erasmus University Institute for Medical Technology Assessment. He previously served as Chair of the Supervisory Board of the Rotterdam Global Health Initiative, President of the Connective Tissue Oncology Society and for 22 years in various Board positions for the European Organisation for Research and Treatment of Cancer (EORTC), including as Vice-President, Chair of the EORTC Early Clinical Studies Group, Chair of the EORTC Soft Tissue and Bone Sarcoma Group, and Chair of the New Drug Advisory Committee. He has authored and co-authored more than 700 papers, mainly with a pharmacologic focus on new drug development.
He received his medical degree from the University of Utrecht, and completed his internship, residency, and fellowship at the Free University Hospital in Amsterdam.
Tracey Weisberg, MD, is the lead physician of New England Cancer Specialists for the past 10 years, manages an active breast cancer practice, has been a principal investigator on 40 clinical trials, and oversees medical house staff at the Maine Medical Center Oncology inpatient unit. An active member of ASCO since 1990, Dr. Weisberg is the immediate past chair of the State Affiliate Council and has been involved in a number of ASCO initiatives, including the CancerLinQ Advisory Committee, the Strategic Planning Task Force, and the Payment Reform Implementation Workgroup, to name a few.
Outside of ASCO, Dr. Weisberg has have served as a board member with Hospice of Southern Maine as well as Northern New England Oncology Association.
Jedd D. Wolchok, MD, PhD, is Chief of the Melanoma and Immunotherapeutics Service in the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSKCC). He is the Associate Director of the Ludwig Center for Cancer Immunotherapy at MSKCC, where he oversees immune monitoring and immunotherapy clinical trials. Dr. Wolchok is an Associate Professor in the Immunology and Microbial Pathogenesis Program at Weill Cornell Graduate School of Medical Sciences of Cornell University and an Associate Professor of Medicine at Weill Cornell Medical College. He is a Member of the Ludwig Institute for Cancer Research.
Dr. Wolchok joined ASCO in 1998 and has taken on numerous leadership roles, including Chair of the Scientific Program Committee and the Best of ASCO® Planning Committee. He has served on the Journal of Clinical Oncology Editorial Board, the Cancer Education Committee, and the Conquer Cancer Foundation Grants Selection Committee.
Dr. Wolchok’s professional achievements have been recognized with the Melanoma Research Foundation Humanitarian Award in 2010 and the Melanoma International Foundation’s Doctor of the Year Award in 2012, among other honors. He was named the Virginia and Daniel K. Ludwig Chair for Clinical Investigation in 2013. In 2014, he was recognized with the American Association for Cancer Research Richard and Hinda Rosenthal Memorial Award and the Giants of Cancer Care in Melanoma Award, as well as being elected to membership in the American Society for Clinical Investigation.
He received his undergraduate degree from Princeton University and his master’s, medical, and doctorate degrees from New York University. He completed his internship and residency at the New York University Medical Center/Bellevue Hospital and his fellowship at MSKCC, where he was named Chief Fellow in Medical Oncology-Hematology.